|Bid||0.1500 x 6348300|
|Ask||0.1500 x 5187600|
|Day's range||0.1450 - 0.1450|
|52-week range||0.1400 - 0.2800|
|Beta (5Y monthly)||1.06|
|PE ratio (TTM)||N/A|
|Earnings date||23 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
2021 has been a significant year for Anatara Lifesciences Limited (ASX:ANR), as we made steps towards progressing our human health products towards clinical trials, successfully completed animal health studies and progressed licensing discussions.
Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal health in humans and animals, invites shareholders to attend a virtual group briefing with Chief Executive Officer, Steven Lydeamore, on Thursday 9 September 2021 at 11:00am AEST.
Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals, is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today to investors.